杜灵彬，主要从事癌症监测及筛查工作及肿瘤流行病学研究，担任浙江省肿瘤防治办公室副主任，浙江省肿瘤医院防治科主任。全面负责浙江省恶性肿瘤一、二级预防工作，肿瘤防控省级标杆。作为起草人参与编写《中国肺癌筛查标准》等5个国家级标准和指南，主导制定浙江省结直肠癌、肺癌和上消化道癌等筛查技术方案。主持国自然面上项目，省自然等课题，作为课题骨干参与承担国家十三五重点研发项目，中科院STS区域重点项目，中国医学科学院重大协同创新项目和省重大科技专项等多个项目。2023年晋级为研究员，近年以第一或通讯作者（含并列）在Plos Medicine 、JAMA Network Open、PNAS、JNCC、IJC、CMJ、BMC Cancer和中华流行病学杂志等中外杂志发表论文50余篇，出版《浙江省肿瘤登记年报》等专著10余本，以主要完成人获得2017年中国抗癌协会科技二等奖和2019年浙江省科技进步二等奖等奖项，获得软著4项。

联系方式：dulb@zjcc.org.cn

研究方向：肿瘤流行病学

科研项目：

1.循环游离DNA甲基化在肺癌筛查中的分子流行病学研究，国家自然科学基金面上项目（82273700，2023.01-2026.12），主持；

2. 智能化多组学肺癌筛查体系的建立和示范应用，中国科学院科技促进发展局STS区域重点项目（KFJ-STS-QYZD-2021-08-001，2021.01-2023.12)，课题负责人；

3. 健康浙江百万人群队列研究，浙江省科技厅（K-20230085,2023.01-2027.12）,课题骨干；

4. 结直肠癌筛查和干预新技术新方案的研究，中国医学科学院医学与健康科技创新工程重大协同创新项目（2017-I2M-1-006,2017.06-2022.12）, 省级课题负责人;

5. 肺癌专病队列研究-肺癌规范化临床诊疗队列, 十三五国家重点研发计划项目精准医学研究（2017YFC0907903,2017.06-2021.12）, 研究任务负责人。

代表性论文(2020-2024年)：

1. Dong X^#, Du L^#, Luo Z^#, Xu Y^#, Wang C^#, Wang F, Cao W, Zhao L, Zheng Y, Zhu H, Xia C, Li J, Du M, Hang D, Ren J, Shi J, Shen H, Chen W, Li N*, He J*; Combining fecal immunochemical testing and questionnaire-based risk assessment in selecting participants for colonoscopy screening in the Chinese National Colorectal Cancer Screening Programs: A population-based cohort study. PLoS Med. 2024 Feb 22;21(2):e1004340. PMC：10883529.

2. Huizhang Li^# , Youqing Wang^#, Weiwei Gong, Chen Zhu , Le Wang , Yaoyao Chen, Lingbin Du*, Xiangdong Cheng*. Cancer survival analysis on population-based cancer registry data in Zhejiang Province, China (2018-2019). J Natl Cancer Cent. 2024;4(1):page. DOI: 10.1016/j.jncc.2023.12.003

3. Wang L^#, Wang Y^#, Wang F^#, Gao Y, Fang Z, Gong W, Li H, Zhu C, Chen Y, Shi L, Du L*, Li N. Disparity in Lung Cancer Screening Among Smokers and Nonsmokers in China: Prospective Cohort Study. JMIR Public Health Surveill. 2023 Mar 14;9:e43586. PMID: 36917151.

4. Zhu J^#, Wang L^#, Gong W^#, Li X, Wang Y, Zhu C, Li H, Shi L*, Yang C*, Du L*. Development and evaluation of a risk assessment tool for the personalized screening of breast cancer in Chinese populations: A prospective cohort study. Cancer. 2023 Nov 2.. PMID: 37916832.

5. Zhao Z, Wang Y, Wu W, Yang Y, Du L*, Dong H*. Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China. JAMA Netw Open. 2022 May 2;5(5):e2213634.

6. Wang, You-Qing^#; Li, Hui-Zhang^#; Gong, Wei-Wei; Chen, Yao-Yao; Zhu, Chen; Wang, Le; Zhong, Jie-Ming*; Du, Ling-Bin*.Cancer incidence and mortality in Zhejiang Province, Southeast China, 2016: a population-based study, Chinese Medical Journal: 2021,134(8): 1959-1966.

7. Ying L^#, Du L^#, Zou R, Shi L, Zhang N, Jin J, Xu C, Zhang F, Zhu C, Wu J, Chen K, Huang M, Wu Y, Zhang Y, Zheng W, Pan X, Chen B, Lin A, Tam JKC, van Dam RM, Lai DTM, Chia KS, Zhou L, Too HP, Yu H, Mao W, Su D. Development of a serum miRNA panel for detection of early stage non-small cell lung cancer. Proc Natl Acad Sci U S A. 2020 ,117(40):25036-25042.

8. Ji M^#, Du L^#, Ma Z^#, Xie J, Huang Y, Wei X, Jiang X, Xu J, Yin R, Wang Y, Dai J, Jin G, Xu L, Zhu C, Hu Z, Ma H, Zhu M*, Shen H*. Circulating C-reactive protein increases lung cancer risk: Results from a prospective cohort of UK Biobank. Int J Cancer. 2022 Jan 1;150(1):47-55.

9. Zhao Z^#, Du L^#, Li Y, Wang L, Wang Y, Yang Y, Dong H. Cost-Effectiveness of Lung Cancer Screening Using Low-Dose Computed Tomography Based on Start Age and Interval in China: Modeling Study. JMIR Public Health Surveill. 2022 Jul 6;8(7):e36425. PMID: 36252229;

10. Li R, He Y, Sun X, Wang N, Zhang M, Wei K, Li H, Dong P, Du L*, Chen W*. The long-term survival of esophageal cancer in elderly patients: A multi-center, retrospective study from China. Cancer Med. 2023 Feb;12(4):4852-4863. doi: 10.1002/cam4.5307.